HITIQ Shareholders Back Funding and Director Fee Resolutions at 2026 General Meeting

HitIQ Limited ( (AU:HIQ) ) has issued an announcement.

HITIQ Limited, a concussion management technology company listed on the ASX, held its General Meeting on 6 February 2026, at which shareholders considered a suite of capital and remuneration-related resolutions. The meeting, where two previously flagged resolutions were withdrawn, saw strong shareholder support via poll for the approval of share issues tied to the conversion of convertible notes, grants of general and specific security interests to lender No Bull Health Pty Ltd, ratification of prior placement securities, and approval of additional placement securities to director Tony Toohey. Investors also backed the issuance of options to the lead manager and multiple resolutions allowing directors to receive securities in lieu of fees, underscoring shareholder endorsement of HITIQ’s current funding structure and governance approach as it continues to execute its growth strategy in concussion technology and athlete safety markets.

The most recent analyst rating on (AU:HIQ) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.

More about HitIQ Limited

HITIQ Limited is an ASX-listed developer of concussion management and athlete safety technology serving sport, clinical and research markets globally. Its flagship PROTEQT platform, co-developed with Shock Doctor, uses instrumented smart mouthguards and an analytics system to deliver real-time head impact data and data-driven safety solutions.

Average Trading Volume: 882,784

Technical Sentiment Signal: Sell

Current Market Cap: A$9.03M

For detailed information about HIQ stock, go to TipRanks’ Stock Analysis page.